Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Ahn, Jin Young; Sohn, Yujin; Lee, Su Hwan; Cho, Yunsuk; Hyun, Jong Hoon; Baek, Yae Jee; Jeong, Su Jin; Kim, Jung Ho; Ku, Nam Su; Yeom, Joon‐Sup; Roh, Juhye; Ahn, Mi Young; Chin, Bum Sik; Kim, Young Sam; Lee, Hyukmin; Yong, Dongeun; Kim, Hyun Ok; Kim, ShinYoung; Choi, Jun Yong

doi:10.3346/jkms.2020.35.e149

Cited by 319 publications

(349 citation statements)

References 18 publications

Supporting

Mentioning

332

Contrasting

Unclassified

Order By: Relevance

“…Among these, we found five relevant articles (one pilot study, one preliminary communication, one novel report, one case report, one descriptive study). [6][7][8][9][10] Extracted details for five studies are presented in Table 1, including the country of study, number of patients, dosage of CPT, mortality, length of hospital stay during transfusion, critical care interventions, clinical outcome, viral load, and adverse events. The five studies include a total of 27 patients who received CPT therapies for COVID-19.…”

Section: Resultsmentioning

confidence: 99%

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Rajendran

Narayanasamy

Rangarajan

et al. 2020

Journal of Medical Virology

308

307

View full text Add to dashboard Cite

show abstract

Section: Resultsmentioning

confidence: 99%

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Rajendran

Narayanasamy

Rangarajan

et al. 2020

Journal of Medical Virology

308

307

View full text Add to dashboard Cite

show abstract

“…A few days later after this initial report, a case report from Korea showed that 2 elderly patients improved after the application of convalescent plasma. They published their results in a Korean journal [11]. One of the two patients was a 71-year-old man with no underlying medical conditions who was initially treated with malaria drugs and needed respiratory support for severe pneumonia.…”

Section: Passive Immunizationmentioning

confidence: 99%

The role of passive immunization in the age of SARS-CoV-2: an update

et al. 2020

View full text Add to dashboard Cite

The rapid spread of the corona virus pandemic is an existential problem for many people in numerous countries. So far, there is no effective vaccine protection or proven therapy available against the SARS-CoV-2 virus. In this review, we describe the role of passive immunization in times of the corona virus. Passive immunization could be a bridging technology to improve the immune defense of critically ill patients until better approaches with effective medications are available.

show abstract

“…Both the patients experienced virological cure after 3 days of treatment with convalescent plasma. The resolution of lung lesions was also observed along with alleviation of other clinical symptoms [40]. Although, the evidence base for immunotherapy with convalescence plasma is supported by only weak quality evidence, it holds promise for future management strategies.…”

Section: Immunotherapy With Convalescent Plasmamentioning

confidence: 98%

Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS CoV-2: A Systematic Literature Review

Subramanian¹,

Nalli²,

Senthil³

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background:Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak is a serious health concern. Repurposing of existing drugs indicated for other conditions seems to be the first choice for immediate therapeutic management. The quality of early evidence favoring the different treatment options needs to be apprised for informed decision making. Methods:In this systematic literature review, we apprised the quality of available evidence for different therapeutic options and also the basis for different treatment guidelines. In order to include all studies that are in different stages of publications, we also included studies from the preprint servers, BioRxiv, MedRxiv and published studies from PubMed. Results:We retrieved 5621 articles and included 20 studies for the systematic review. Based on our study, chloroquine/hydroxychloroquine either alone or in combination with azithromycin, remdesivir, corticosteroids, convalescent sera, ritonavir/lopinavir and arbidol were evaluated as therapeutic options. The data from different study designs reveal contradictory findings except for convalescent sera for which the evidence available is only from case series. Based on these early evidence, various national guidelines recommend remdesivir, convalescent sera, corticosteroids, hydroxychloroquine in different sub set of patients. Conclusion:Establishing consensus with respect to the endpoints to be assessed for respiratory viruses may enhance the quality of evidences in case of future pandemics. Further clinical evidence from the ongoing trials may lead to evolution of treatment guidelines with the addition of more therapeutic options.

show abstract

Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea

Cited by 319 publications

References 18 publications

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

Convalescent plasma transfusion for the treatment of COVID‐19: Systematic review

The role of passive immunization in the age of SARS-CoV-2: an update

Perspectives on the Early Quality of Evidence Guiding the Therapeutic Management of SARS CoV-2: A Systematic Literature Review

Contact Info

Product

Resources

About